EGFR and non-small cell lung carcinoma: The secondary EGFR mutations [10] and activations of alternative RTKs creating a bypass track [11, 12] have been proposed as reasons for the failed responses to EGFR TKIs, yet fail to fully account for the development of acquired resistance to these drugs in NSCLC patients.